DK0787191T4 - Nukleotidsekvenser af HIV-1 type (eller undertype) O retrovirusantigener - Google Patents

Nukleotidsekvenser af HIV-1 type (eller undertype) O retrovirusantigener

Info

Publication number
DK0787191T4
DK0787191T4 DK95935996.9T DK95935996T DK0787191T4 DK 0787191 T4 DK0787191 T4 DK 0787191T4 DK 95935996 T DK95935996 T DK 95935996T DK 0787191 T4 DK0787191 T4 DK 0787191T4
Authority
DK
Denmark
Prior art keywords
hiv
subtype
type
nucleotide sequences
retrovirus antigens
Prior art date
Application number
DK95935996.9T
Other languages
Danish (da)
English (en)
Other versions
DK0787191T3 (da
Inventor
Frana Ois Clavel
Andrew Borman
Denise Guetard
Luc Montagnier
De Saint-Martin Jacqueline Donjon
Jacques H M Cohen
Caroline Quillent
Pierre Charneau
Original Assignee
Pasteur Institut
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26231483&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK0787191(T4) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from FR9412554A external-priority patent/FR2726006B1/fr
Priority claimed from FR9502526A external-priority patent/FR2731225B1/fr
Application filed by Pasteur Institut filed Critical Pasteur Institut
Publication of DK0787191T3 publication Critical patent/DK0787191T3/da
Application granted granted Critical
Publication of DK0787191T4 publication Critical patent/DK0787191T4/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G01N33/56988—HIV or HTLV
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/975—Kit

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • AIDS & HIV (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Communicable Diseases (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Oncology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DK95935996.9T 1994-10-20 1995-10-20 Nukleotidsekvenser af HIV-1 type (eller undertype) O retrovirusantigener DK0787191T4 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR9412554A FR2726006B1 (fr) 1994-10-20 1994-10-20 Sequences nucleotidiques codant des antigenes d'un retrovirus du type vih-1 groupe o
FR9502526A FR2731225B1 (fr) 1995-03-03 1995-03-03 Peptides de glycoproteine transmembranaire d'enveloppe et de proteine de capside du retrovirus humain du type hiv-1 et peptides presentant avec eux une parente immunologique
PCT/FR1995/001391 WO1996012809A2 (fr) 1994-10-20 1995-10-20 Sequences nucleotidiques d'antigenes retroviraux vih-1 groupe (ou sous-groupe) o

Publications (2)

Publication Number Publication Date
DK0787191T3 DK0787191T3 (da) 2008-02-04
DK0787191T4 true DK0787191T4 (da) 2012-01-30

Family

ID=26231483

Family Applications (1)

Application Number Title Priority Date Filing Date
DK95935996.9T DK0787191T4 (da) 1994-10-20 1995-10-20 Nukleotidsekvenser af HIV-1 type (eller undertype) O retrovirusantigener

Country Status (12)

Country Link
US (3) US6399294B1 (enExample)
EP (2) EP0787191B2 (enExample)
JP (4) JP4278174B2 (enExample)
CN (3) CN102134609A (enExample)
AT (1) ATE374253T1 (enExample)
AU (3) AU715731B2 (enExample)
CA (2) CA2202408C (enExample)
DE (1) DE69535601T3 (enExample)
DK (1) DK0787191T4 (enExample)
ES (1) ES2293643T5 (enExample)
PT (1) PT787191E (enExample)
WO (1) WO1996012809A2 (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT787191E (pt) * 1994-10-20 2007-12-06 Pasteur Institut Sequências nucleotídicas de antigénios retroviraisde vih do tipo (ou sub-tipo) o
AU710468B2 (en) * 1995-01-27 1999-09-23 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Methods for sensitive detection of reverse transcriptase
DE19505262C2 (de) * 1995-02-16 1998-06-18 Behring Diagnostics Gmbh Retrovirus aus der HIV-Gruppe und dessen Verwendung
IL132166A0 (en) * 1997-04-09 2001-03-19 Pasteur Sanofi Diagnostics Synthetic peptides which can be used in biological tests for the detection of infections due to group o hiv-1 viruses
FR2761993B1 (fr) * 1997-04-09 1999-05-21 Pasteur Sanofi Diagnostics Peptides synthetiques utilisables dans les essais biologiques pour la detection des infections dues aux virus vih 1 groupe 0
FR2775287B1 (fr) * 1998-02-24 2000-11-24 Pasteur Sanofi Diagnostics Peptides synthetiques consensus utilisables dans les essais biologiques pour la detection des infections dues aux virus vih 1 du groupe o
US6511801B1 (en) 1997-07-18 2003-01-28 Innogenetics, N.V. HIV-1 group O antigens and uses thereof
US6846905B2 (en) 1997-08-15 2005-01-25 Abbott Laboratories Antigen constructs useful in the detection and differentiation of antibodies to HIV
US5922533A (en) * 1997-08-15 1999-07-13 Abbott Laboratories Rapid assay for simultaneous detection and differentiation of antibodies to HIV groups
AU2345399A (en) * 1998-01-28 1999-08-16 Universal Health-Watch, Inc. Divergent hiv-1 peptides
CN1061092C (zh) * 1998-02-27 2001-01-24 中国科学院上海生物化学研究所 白色念珠菌具有逆转录转座子结构的元件
CA2288869A1 (en) * 1998-03-04 1999-09-10 Mary Ann Childs Rapid confirmatory test for microbial infections
AU3670999A (en) * 1998-04-30 1999-11-16 Universal Health-Watch, Inc. Immunoassay with mixed peptides
WO1999062945A2 (en) * 1998-06-05 1999-12-09 Peptide Solutions, Inc. Peptide antigens for detection of hiv, hcv and other microbial infections
CA2676762C (en) * 1998-11-30 2015-12-29 Ortho-Clinical Diagnostics, Inc. Peptides for the detection of hiv-1 group o
EP1187939B9 (en) * 1999-07-09 2009-08-12 Gen-Probe Incorporated Detection of hiv-1 by nucleic acid amplification
US6818392B2 (en) 2000-12-06 2004-11-16 Abbott Laboratories Monoclonal antibodies to human immunodeficiency virus and uses thereof
EP2251442B9 (en) 2003-12-19 2012-04-25 Gen-Probe Incorporated Compositions, methods and kits for detecting the nucleic acids of HIV-1 and HIV-2
TW200613554A (en) * 2004-06-17 2006-05-01 Wyeth Corp Plasmid having three complete transcriptional units and immunogenic compositions for inducing an immune response to HIV
AU2005335203A1 (en) 2004-09-08 2007-02-15 The United States Of America As Represented By The Secretary Of Health And Human Services, Nih Compositions and methods for the detection of HIV-1/HIV-2 infection
EP1989326A4 (en) 2006-01-17 2009-09-30 Health Research Inc BIO-HETERODUPLEX TRACKING TEST
US8405379B1 (en) 2008-09-18 2013-03-26 Luc Montagnier System and method for the analysis of DNA sequences in biological fluids
US20130302364A1 (en) * 2010-11-10 2013-11-14 Laboratorios Del Dr. Esteve, S.A. Highly immunogenic hiv p24 sequences
EP2864787B1 (en) * 2012-06-22 2017-11-01 Bio-Rad Laboratories, Inc. Human factor xiii as a normalization control for immunoassays
US9823249B2 (en) * 2012-12-12 2017-11-21 Brigham And Women's Hospital, Inc. System and method for detecting pathogens
KR102056520B1 (ko) 2017-03-24 2019-12-18 (주)셀아이콘랩 인간 섬유아세포에서 콜라겐 합성 촉진 및 콜라겐 분해 효소 활성화 억제를 유도하는 펩타이드를 함유한 화장품 조성물 및 제조방법
CN108997482B (zh) 2018-08-09 2025-09-09 东莞市朋志生物科技有限公司 用于检测hiv-1的合成肽

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5030714A (en) 1986-06-23 1991-07-09 Institut Pasteur Variant of LAV viruses
JPH0762031B2 (ja) * 1986-12-30 1995-07-05 アメリカ合衆国 エイズウイルスおよびエイズウイルスのタンパク質に対する細胞性免疫を誘導する合成ペプチド
NO881151L (no) * 1987-03-27 1988-09-28 Syntello Ab Syntetisk hiv-1-antigen.
CA1339363C (en) * 1987-05-01 1997-08-26 Alan Ray Flesher Monoclonal antibodies to specific antigenic regions of the human immunodeficiency virus and methods for use
JPH0215098A (ja) * 1987-05-18 1990-01-18 Virovahl Sa Ｈｉｖ−１感染検出用合成ペプチド杭原、その組成物およびその使用方法
US5019387A (en) * 1987-09-08 1991-05-28 Duke University Production of antibodies to HIV
IL88963A (en) * 1988-01-27 1996-05-14 Iaf Biochem Int Circular synthetic peptides and their mixtures for the detection of VIH antibodies and for the formation of vaccines
EP0330359A3 (en) 1988-02-25 1991-06-05 Bio-Rad Laboratories, Inc. Composition useful in the diagnosis and treating of hiv-1 infection
ES2072853T3 (es) 1988-06-09 1995-08-01 Innogenetics Nv Retrovirus hiv-3 y su utilizacion.
ATE135113T1 (de) * 1988-12-20 1996-03-15 Clarity Technologies Inc Synthetische hiv ähnliche peptide, deren zusammensetzungen und verwendungen
GB8910145D0 (en) * 1989-05-03 1989-06-21 Connaught Lab Synthetic peptides for an hiv-1 vaccine
ZA903492B (en) * 1989-05-15 1991-02-27 Akzo Nv T-lymphotropic retrovirus monoclonal antibodies
FR2647810B1 (fr) * 1989-06-02 1994-07-22 Pasteur Institut Amorces oligonucleotidiques pour l'amplification du genome des retrovirus du type hiv-2 et siv, et leurs applications au diagnostic in vitro des infections dues a ces virus
DE3934366A1 (de) * 1989-10-14 1991-04-18 Chemotherapeutisches Forschungsinstitut Georg Speyer Haus Vakzine zum schutz vor hiv-virusinfektionen, verfahren zu ihrer herstellung und ihre verwendung als diagnostikum und immuntherapeutikum
US5480967A (en) * 1990-01-05 1996-01-02 United Biomedical, Inc. HIV-1 core protein fragments
IL99077A0 (en) * 1990-08-13 1992-07-15 Merck & Co Inc New embodiments of the hiv principal neutralizing determinant and pharmaceutical compositions containing them
JPH06500923A (ja) * 1990-09-21 1994-01-27 カイロン　コーポレイション パッケージング細胞
US7115554B1 (en) 1993-05-06 2006-10-03 Acorda Therapeutics, Inc. Methods of increasing myotube formation or survival or muscle cell mitogenesis differentiation or survival using neuregulin GGF III
JP2541030B2 (ja) * 1991-04-22 1996-10-09 富士ゼロックス株式会社 ヒドロキシインジウムフタロシアニンの新規結晶及びそれを用いた電子写真感光体
JP3443809B2 (ja) * 1992-03-06 2003-09-08 エヌ・ブイ・インノジェネティクス・ソシエテ・アノニム 免疫学的に重要なエピトープに相当するペプチドの決定方法、及び免疫学的に重要なエピトープに相当するビオチニル化ペプチド又は抗体の決定のための方法におけるその利用、その調製方法及びそれを含む組成物
ES2053413T3 (es) * 1992-05-14 1997-11-16 Polymun Scient Immunbio Forsch Peptidos que inducen anticuerpos que neutralizan aislados de vih-1 geneticamente divergentes.
JP3207535B2 (ja) 1992-08-07 2001-09-10 森永乳業株式会社 抗酸化剤
ES2126620T5 (es) 1992-10-06 2010-05-21 Siemens Healthcare Diagnostics Products Gmbh Retrovirus del grupo de los vih y su utilizacion.
WO1994028871A1 (en) 1993-06-07 1994-12-22 Endocon, Inc. Implant stimulated cellular immunity
KR960703136A (ko) 1993-06-09 1996-06-19 미첼 클레인 탠덤 합성 hiv-1 펩티드들
FR2707091B1 (fr) * 1993-06-30 1997-04-04 Cohen Haguenauer Odile Vecteur rétroviral pour le transfert et l'expression de gènes dans des cellules eucaryotes.
PT787191E (pt) 1994-10-20 2007-12-06 Pasteur Institut Sequências nucleotídicas de antigénios retroviraisde vih do tipo (ou sub-tipo) o
DE19622088A1 (de) 1996-05-31 1997-12-04 Boehringer Mannheim Gmbh Anti-HIV-Antikörper als Kontrollproben

Also Published As

Publication number Publication date
DE69535601T2 (de) 2008-07-10
JP4589420B2 (ja) 2010-12-01
JP2010172335A (ja) 2010-08-12
US8236324B2 (en) 2012-08-07
ES2293643T5 (es) 2012-02-02
JPH10509587A (ja) 1998-09-22
EP1849869A3 (fr) 2011-05-18
US20030049604A1 (en) 2003-03-13
US7157225B2 (en) 2007-01-02
DE69535601D1 (de) 2007-11-08
DK0787191T3 (da) 2008-02-04
ATE374253T1 (de) 2007-10-15
JP2009240315A (ja) 2009-10-22
AU2005202281A1 (en) 2005-06-16
DE69535601T3 (de) 2012-04-05
US20080261197A1 (en) 2008-10-23
CN102134609A (zh) 2011-07-27
CA2652992A1 (fr) 1996-05-02
AU2005202281B2 (en) 2009-06-11
CN1147586C (zh) 2004-04-28
EP0787191A2 (fr) 1997-08-06
AU3808995A (en) 1996-05-15
CN1651457A (zh) 2005-08-10
US6399294B1 (en) 2002-06-04
JP2008271974A (ja) 2008-11-13
CA2202408C (fr) 2012-03-06
WO1996012809A3 (fr) 1996-06-20
EP1849869A2 (fr) 2007-10-31
CA2202408A1 (fr) 1996-05-02
PT787191E (pt) 2007-12-06
ES2293643T3 (es) 2008-03-16
WO1996012809A2 (fr) 1996-05-02
CA2652992C (fr) 2014-10-07
EP0787191B2 (fr) 2011-10-26
CN1164258A (zh) 1997-11-05
JP4278174B2 (ja) 2009-06-10
AU2009213045A1 (en) 2009-10-08
AU715731B2 (en) 2000-02-10
EP0787191B1 (fr) 2007-09-26
AU2009213045B2 (en) 2012-12-20
CN1651457B (zh) 2010-07-28

Similar Documents

Publication Publication Date Title
DK0787191T4 (da) Nukleotidsekvenser af HIV-1 type (eller undertype) O retrovirusantigener
DK0589004T3 (da) Fremgangsmåde til bestemmelse af peptider, som hører til immunologisk vigtige epitoper af HCV
ES2016426A6 (es) Un procedimiento para detectar la presencia de anticuerpos frente a virus del sida en el suero humano.
NO870412L (no) Peptider.
DE3588248D1 (de) LAV-Antigene und -Peptide
KR950032278A (ko) 사람 면역결핍 바이러스 그룹의 레트로바이러스로부터 유래된 펩타이드 및 이의 용도
FI935808A0 (fi) Hepatit-C-virus (HCV) polypeptider
DE3588134D1 (de) Fusionen von AIDS-verwandten Polypeptiden
DE69111440D1 (de) Methoden und zusammensetzungen zur impfung gegen hiv.
FI881418A7 (fi) Synteettiset peptidiantigeenit HIV-1 -infektion toteamiseksi.
EA200000528A1 (ru) Способ получения вакцин для предупреждения патогенных эффектов, связанных с ретровирусной инфекцией
ES2072928T3 (es) Antigenos de celulas de islotes pancreaticos obtenidos por clonaje molecular.
ATE114713T1 (de) Biomasse zur produktion von virus/virusantigen.
ATE108457T1 (de) Synthetische antigene zur bestimmung der aids- bezogenen, von lav-2 verursachten krankheiten.
DE3579856D1 (de) Immunulogischer test zur bestimmung von gemeinsamen, bestimmenden hepatitis-b-antikoerpern.
ATE435034T1 (de) Expression und charakterisierung eines hiv-1 hüllproteins, das mit einer breitreaktiven neutralisierenden antikörperantwort assoziiert ist.
TR27329A (tr) Yeni metazoan parazit antigenler, bunlari kodlayan nükleik asidler.
ATE64783T1 (de) Nachweis von human-t-zellen-leukemievirus des typs-iii.
Sotirov Immunological studies into chicken erythroblastosis.
York The Jaagsiekte retrovirus: Isolation and comparison with a new South African lentivirus.
ATE62019T1 (de) Verfahren zur herstellung von hcmvglykoproteinen, antikoerper dagegen und hcmvvakzine und dazu zu verwendende rekombinante vektoren.
ATE55257T1 (de) Verfahren zur herstellung von hochgereinigten, hepatitis-b-virus-infektionsfreien gammaglobulinen.